Albert David Ltd
Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products[1]
- Market Cap ₹ 420 Cr.
- Current Price ₹ 735
- High / Low ₹ 959 / 663
- Stock P/E 43.7
- Book Value ₹ 690
- Dividend Yield 0.68 %
- ROCE 6.45 %
- ROE 4.39 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.07 times its book value
Cons
- The company has delivered a poor sales growth of 1.52% over past five years.
- Company has a low return on equity of 12.5% over last 3 years.
- Earnings include an other income of Rs.27.2 Cr.
- Dividend payout has been low at 13.2% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 287 | 317 | 318 | 293 | 285 | 316 | 320 | 246 | 313 | 341 | 362 | 345 | 323 | |
| 254 | 281 | 286 | 266 | 267 | 286 | 289 | 227 | 272 | 297 | 315 | 342 | 325 | |
| Operating Profit | 33 | 37 | 31 | 27 | 18 | 30 | 30 | 19 | 41 | 44 | 47 | 3 | -2 |
| OPM % | 11% | 12% | 10% | 9% | 6% | 10% | 10% | 8% | 13% | 13% | 13% | 1% | -1% |
| 1 | 2 | 43 | 8 | 9 | 15 | 7 | 17 | 16 | 15 | 58 | 30 | 27 | |
| Interest | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 2 |
| Depreciation | 11 | 15 | 9 | 8 | 8 | 7 | 8 | 8 | 9 | 9 | 7 | 7 | 9 |
| Profit before tax | 18 | 20 | 63 | 26 | 18 | 38 | 29 | 27 | 47 | 51 | 97 | 25 | 14 |
| Tax % | 32% | 32% | 24% | 39% | 45% | 29% | 34% | 19% | 25% | 29% | 22% | 32% | |
| 13 | 14 | 48 | 16 | 10 | 27 | 19 | 22 | 35 | 36 | 75 | 17 | 10 | |
| EPS in Rs | 22.02 | 24.00 | 84.10 | 27.96 | 17.24 | 46.68 | 33.59 | 38.79 | 61.78 | 63.38 | 132.15 | 30.14 | 16.84 |
| Dividend Payout % | 23% | 23% | 7% | 20% | 32% | 13% | 21% | 15% | 15% | 14% | 9% | 17% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 3% |
| TTM: | -10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -2% |
| 3 Years: | -20% |
| TTM: | -76% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 13% |
| 3 Years: | 9% |
| 1 Year: | -16% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 85 | 87 | 131 | 177 | 180 | 205 | 217 | 239 | 274 | 306 | 377 | 387 | 388 |
| 42 | 30 | 20 | 30 | 28 | 0 | 2 | 2 | 6 | 5 | 3 | 12 | 41 | |
| 66 | 71 | 67 | 71 | 76 | 84 | 95 | 95 | 116 | 106 | 112 | 107 | 98 | |
| Total Liabilities | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 | 533 |
| 67 | 49 | 44 | 87 | 83 | 77 | 91 | 84 | 88 | 80 | 83 | 99 | 95 | |
| CWIP | 3 | 5 | 5 | 9 | 5 | 5 | 2 | 1 | 1 | 3 | 7 | 2 | 5 |
| Investments | 16 | 16 | 48 | 59 | 68 | 113 | 122 | 138 | 183 | 193 | 273 | 260 | 277 |
| 111 | 122 | 127 | 130 | 134 | 99 | 106 | 119 | 130 | 148 | 135 | 151 | 156 | |
| Total Assets | 198 | 193 | 224 | 285 | 290 | 295 | 320 | 341 | 401 | 423 | 498 | 511 | 533 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 28 | 68 | 20 | 30 | 32 | 30 | 37 | 40 | 11 | 46 | -28 | |
| -24 | -9 | -38 | -36 | -11 | -19 | -20 | -37 | -40 | -5 | -33 | 23 | |
| -2 | -18 | -18 | 7 | -5 | -17 | -10 | -2 | -2 | -6 | -8 | 0 | |
| Net Cash Flow | -5 | 1 | 12 | -10 | 15 | -4 | 0 | -2 | -1 | -1 | 4 | -5 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 47 | 41 | 41 | 35 | 25 | 34 | 29 | 29 | 32 | 30 | 29 |
| Inventory Days | 191 | 176 | 187 | 217 | 173 | 151 | 148 | 151 | 124 | 149 | 126 | 201 |
| Days Payable | 135 | 103 | 102 | 117 | 127 | 102 | 132 | 104 | 96 | 95 | 98 | 118 |
| Cash Conversion Cycle | 111 | 120 | 126 | 141 | 81 | 74 | 50 | 76 | 57 | 87 | 58 | 112 |
| Working Capital Days | 21 | 27 | 25 | 24 | 10 | 21 | 18 | -10 | -34 | 14 | -13 | 6 |
| ROCE % | 18% | 18% | 17% | 15% | 7% | 18% | 14% | 12% | 17% | 17% | 28% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Feb - Newspaper Publication of Extract of Unaudited Financial Result for the third quarter and nine months ended 31st December, 2025
- Unaudited Financial Results For The Third Quarter And Nine Months Ended 31St December, 2025 11 Feb
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th February, 2026
11 Feb - Approved unaudited results for third quarter and nine months ended 31 Dec 2025; limited review attached.
-
Board Meeting Intimation for To Consider And Approve Unaudited Financial Results For The Third Quarter And Nine Months Ended 31St December 2025.
2 Feb - Board meeting on Feb 11, 2026 to approve unaudited Q3 and nine-month results ended Dec 31, 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
17 Jan - Snehal Tushar Bhosale resigned as EA to MD & CEO effective close of January 16, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.